We Offer Worldwide Shipping
Login Wishlist

Ethyl2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate

$77

  • Brand : BIOFRON

  • Catalogue Number : BN-O1254

  • Specification : 98%(HPLC)

  • CAS number : 238749-50-3

  • Formula : C9H8BrNO2S

  • Molecular Weight : 274.14

  • PUBCHEM ID : 13164349

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1254

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

274.14

Appearance

Botanical Source

Structure Type

Category

SMILES

CCOC(=O)C1=CC2=C(N1)C=C(S2)Br

Synonyms

Ethyl 2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate/ethyl 2-bromothieno<3,2-b>pyrrole-5-carboxylate/4H-Thieno[3,2-b]pyrrole-5-carboxylic acid, 2-bromo-, ethyl ester/QC-1864

IUPAC Name

ethyl 2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate

Density

1.7±0.1 g/cm3

Solubility

Flash Point

195.0±26.5 °C

Boiling Point

398.8±37.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

KXGSKTSSCQBDOA-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:238749-50-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

23865419

Abstract

Background
Nonsense-Mediated decay (NMD) selectively degrades mRNA transcripts that carry premature stop codons. NMD is often triggered by alternative splicing (AS) modifications introducing such codons. NMD plays an important regulatory role in brain neurons, but the in vivo dynamics of AS and NMD changes in neurological diseases and under treatment were scarcely explored.

Results
Here, we report exon arrays analysis of leukocyte mRNA AS events prior to and following Deep Brain Stimulation (DBS) neurosurgery, which efficiently improves the motor symptoms of Parkinson’s disease (PD), the leading movement disorder, and is increasingly applied to treat other diseases. We also analyzed publicly available exon array dataset of whole blood cells from mixed early and advanced PD patients. Our in-house exon array dataset of leukocyte transcripts was derived from advanced PD patients’ pre- and post-DBS stimulation and matched healthy control volunteers. The mixed cohort exhibited 146 AS changes in 136 transcripts compared to controls, including 9 NMD protein-level assessed events. In comparison, PD patients from our advanced cohort differed from healthy controls by 319 AS events in 280 transcripts, assessed as inducing 27 protein-level NMD events. DBS stimulation induced 254 AS events in 229 genes as compared to the pre-DBS state including 44 NMD inductions. A short, one hour electrical stimulus cessation caused 234 AS changes in 125 genes compared to ON-stimulus state, 22 of these were assessed for NMD. Functional analysis highlighted disease-induced DNA damage and inflammatory control and its reversal under ON and OFF stimulus as well as alternative splicing in all the tested states.

Conclusions
The study findings indicate a potential role for NMD both in PD and following electrical brain stimulation. Furthermore, our current observations entail future implications for developing therapies for PD, and for interfering with the impaired molecular mechanisms that underlie PD and other neurodegenerative and neurological disorders, as well as DBS-treatable conditions in general.

KEYWORDS

Alternative splicing, Deep brain stimulation, Exon microarrays, Leukocytes, Nonsense-Mediated decay, Parkinson’s disease

Title

Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson’s patients leukocytes

Author

Lilach Soreq, Hagai Bergman, Zvi Israel, Hermona Soreq

Publish date

2013;


Description :

Empty ...